% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Esen:272836,
author = {B. Esen and K. Herrmann$^*$ and S. Bavbek and Y. Kordan and
D. Tilki and T. Esen},
title = {{P}rostate-specific {M}embrane {A}ntigen {P}ositron
{E}mission {T}omography as a {B}iomarker to {A}ssess
{T}reatment {R}esponse in {P}atients with {A}dvanced
{P}rostate {C}ancer.},
journal = {European urology focus},
volume = {9},
number = {4},
issn = {2405-4569},
address = {Amsterdam},
publisher = {Elsevier},
reportid = {DKFZ-2023-00409},
pages = {596-605},
year = {2023},
note = {2023 Jul;9(4):596-605},
abstract = {Prostate-specific membrane antigen (PSMA)-targeted positron
emission tomography (PET) has superior accuracy for
detection of metastatic lesions in patients with prostate
cancer (PC). Although PSMA PET has a prominent role in
primary and secondary imaging of PC, data on its role in
assessing treatment response in advanced PC are limited.To
review current data in the literature regarding the impact
of antiandrogen therapy on PSMA expression of metastatic
sites and the role of serial (baseline and at least 1
follow-up scan) PSMA PET to assess treatment response in
patients with metastatic PC.A comprehensive literature
search in the PubMed database was performed using the terms
'PSMA expression prostate', 'PSMA regulation', 'PSMA PET
response assessment', and 'serial PSMA PET'.Serial PSMA PET
studies (baseline and at least 1 follow-up scan) provide
valuable data regarding PSMA expression changes after
systemic treatment in patients with metastatic PC. PSMA
PET-detected flare and upregulation of PSMA expression
following hormonal intervention seem to be early events
resolving after 3 mo of treatment. PSMA PET imaging is
essential in selecting patients for 177Lu-PSMA radioligand
therapy (RLT). Growing evidence favors its use in assessing
treatment responses after RLT. Preliminary evidence
indicates the value of PSMA PET for assessment of the
treatment response in patients receiving systemic treatment
other than RLT for metastatic PC.PSMA flare following
antiandrogen therapy seems to be an early event and thus PET
scans should be performed no earlier than 3 mo after the
start of treatment. PSMA PET has a promising role in
tailoring treatment according to the specific needs of
individual patients and assessing responses following
systemic treatment in patients with advanced PC.This review
describes how a sensitive imaging method can be used to
assess the tumor response to treatment for metastatic
prostate cancer.},
subtyp = {Review Article},
keywords = {Positron emission tomography (Other) / Prostate cancer
(Other) / Prostate-specific membrane antigen (Other) /
Response to therapy (Other) / Serial imaging (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36842919},
doi = {10.1016/j.euf.2023.02.001},
url = {https://inrepo02.dkfz.de/record/272836},
}